Published in Nat Med on October 12, 2015
Complete Pathologic Response Rectal Cancers (CORSiCA) | NCT03351959
The mPower study, Parkinson disease mobile data collected using ResearchKit. Sci Data (2016) 2.19
Association of SMAD4 mutation with patient demographics, tumor characteristics, and clinical outcomes in colorectal cancer. PLoS One (2017) 1.39
Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer. Nat Rev Cancer (2017) 1.39
Metastases and Colon Cancer Tumor Growth Display Divergent Responses to Modulation of Canonical WNT Signaling. PLoS One (2016) 1.38
BRAF-Mutated Colorectal Cancer: What Is the Optimal Strategy for Treatment? Curr Treat Options Oncol (2017) 1.06
Wnt signaling in cancer. Oncogene (2016) 0.95
Location of Primary Tumor and Benefit From Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer. Oncologist (2016) 0.89
Clinical Outcome From Oxaliplatin Treatment in Stage II/III Colon Cancer According to Intrinsic Subtypes: Secondary Analysis of NSABP C-07/NRG Oncology Randomized Clinical Trial. JAMA Oncol (2016) 0.88
Molecular Biomarkers in the Personalized Treatment of Colorectal Cancer. Clin Gastroenterol Hepatol (2016) 0.88
Molecular dissection of colorectal cancer in pre-clinical models identifies biomarkers predicting sensitivity to EGFR inhibitors. Nat Commun (2017) 0.87
Molecular pathological classification of colorectal cancer. Virchows Arch (2016) 0.85
BCL9/9L-β-catenin Signaling is Associated With Poor Outcome in Colorectal Cancer. EBioMedicine (2015) 0.85
Integrating Colon Cancer Microarray Data: Associating Locus-Specific Methylation Groups to Gene Expression-Based Classifications. Microarrays (Basel) (2015) 0.84
H19 Noncoding RNA, an Independent Prognostic Factor, Regulates Essential Rb-E2F and CDK8-β-Catenin Signaling in Colorectal Cancer. EBioMedicine (2016) 0.84
Cytokine-Induced Modulation of Colorectal Cancer. Front Oncol (2016) 0.84
ARID1A loss impairs enhancer-mediated gene regulation and drives colon cancer in mice. Nat Genet (2016) 0.84
Clinical Significance and Prognostic Relevance of Microsatellite Instability in Sporadic Colorectal Cancer Patients. Int J Mol Sci (2017) 0.83
Expression profiling of budding cells in colorectal cancer reveals an EMT-like phenotype and molecular subtype switching. Br J Cancer (2016) 0.81
High microsatellite instability (MSI-H) colorectal carcinoma: a brief review of predictive biomarkers in the era of personalized medicine. Fam Cancer (2016) 0.81
Oncogenic Kras drives invasion and maintains metastases in colorectal cancer. Genes Dev (2017) 0.81
TGFβ signaling directs serrated adenomas to the mesenchymal colorectal cancer subtype. EMBO Mol Med (2016) 0.80
Determinants of metastatic competency in colorectal cancer. Mol Oncol (2017) 0.80
A multigene mutation classification of 468 colorectal cancers reveals a prognostic role for APC. Nat Commun (2016) 0.80
Algorithmic methods to infer the evolutionary trajectories in cancer progression. Proc Natl Acad Sci U S A (2016) 0.79
Transcriptional upregulation of c-MET is associated with invasion and tumor budding in colorectal cancer. Oncotarget (2016) 0.79
Targeting mutant RAS in patient-derived colorectal cancer organoids by combinatorial drug screening. Elife (2016) 0.79
Molecular Subtypes and Personalized Therapy in Metastatic Colorectal Cancer. Curr Colorectal Cancer Rep (2016) 0.78
Higher Order Chromatin Modulator Cohesin SA1 Is an Early Biomarker for Colon Carcinogenesis: Race-Specific Implications. Cancer Prev Res (Phila) (2016) 0.78
PTEN mRNA expression is less pronounced in left- than right-sided colon cancer: a retrospective observational study. BMC Cancer (2016) 0.78
From tumour heterogeneity to advances in precision treatment of colorectal cancer. Nat Rev Clin Oncol (2016) 0.78
Collagen-rich stroma in aggressive colon tumors induces mesenchymal gene expression and tumor cell invasion. Oncogene (2016) 0.78
CD133+CD24lo defines a 5-Fluorouracil-resistant colon cancer stem cell-like phenotype. Oncotarget (2016) 0.78
Intestinal lymphatic vasculature: structure, mechanisms and functions. Nat Rev Gastroenterol Hepatol (2017) 0.78
Immunological Landscape and Clinical Management of Rectal Cancer. Front Immunol (2016) 0.77
Gut macrophage phenotype is dependent on the tumor microenvironment in colorectal cancer. Clin Transl Immunology (2016) 0.77
Loss of KCNQ1 expression in stage II and stage III colon cancer is a strong prognostic factor for disease recurrence. Br J Cancer (2016) 0.77
Clinicopathologic and Molecular Features of Colorectal Adenocarcinoma with Signet-Ring Cell Component. PLoS One (2016) 0.77
Transforming Growth Factor β Superfamily Signaling in Development of Colorectal Cancer. Gastroenterology (2016) 0.77
Bone morphogenetic protein and Notch signalling crosstalk in poor-prognosis, mesenchymal-subtype colorectal cancer. J Pathol (2017) 0.77
Differential Radiographic Appearance of BRAF V600E-Mutant Metastatic Colorectal Cancer in Patients Matched by Primary Tumor Location. J Natl Compr Canc Netw (2016) 0.77
A Phase 1b Dose-Escalation Study of Encorafenib (LGX818) and Cetuximab With or Without Alpelisib in Metastatic BRAF-Mutant Colorectal Cancer. Cancer Discov (2017) 0.76
Prognostic gene expression profiling in esophageal cancer: a systematic review. Oncotarget (2016) 0.76
Multi-omics landscapes of colorectal cancer subtypes discriminated by an individualized prognostic signature for 5-fluorouracil-based chemotherapy. Oncogenesis (2016) 0.76
Using Big Data to Discover Diagnostics and Therapeutics for Gastrointestinal and Liver Diseases. Gastroenterology (2016) 0.76
Large variety in a panel of human colon cancer organoids in response to EZH2 inhibition. Oncotarget (2016) 0.76
MicroRNA MIR21 (miR-21) and PTGS2 Expression in Colorectal Cancer and Patient Survival. Clin Cancer Res (2016) 0.76
SNP rs16906252C>T Is an Expression and Methylation Quantitative Trait Locus Associated with an Increased Risk of Developing MGMT-Methylated Colorectal Cancer. Clin Cancer Res (2016) 0.76
The Epigenomics of Embryonic Pathway Signaling in Colorectal Cancer. Front Pharmacol (2017) 0.76
The immune contexture in cancer prognosis and treatment. Nat Rev Clin Oncol (2017) 0.75
MYC Deregulation in Primary Human Cancers. Genes (Basel) (2017) 0.75
Gankyrin sustains PI3K/GSK-3β/β-catenin signal activation and promotes colorectal cancer aggressiveness and progression. Oncotarget (2016) 0.75
Clinical Implications and Future Perspectives of Circulating Tumor Cells and Biomarkers in Clinical Outcomes of Colorectal Cancer. Transl Oncol (2016) 0.75
Next generation sequencing identifies 'interactome' signatures in relapsed and refractory metastatic colorectal cancer. J Gastrointest Oncol (2017) 0.75
Patterns of Sociodemographic and Clinicopathologic Characteristics of Stages II and III Colorectal Cancer Patients by Age: Examining Potential Mechanisms of Young-Onset Disease. J Cancer Epidemiol (2017) 0.75
Comprehensive investigation of a novel differentially expressed lncRNA expression profile signature to assess the survival of patients with colorectal adenocarcinoma. Oncotarget (2017) 0.75
Mutanome and expression of immune response genes in microsatellite stable colon cancer. Oncotarget (2016) 0.75
A COL11A1-correlated pan-cancer gene signature of activated fibroblasts for the prioritization of therapeutic targets. Cancer Lett (2016) 0.75
Gastric Cancer Genomics: Advances and Future Directions. Cell Mol Gastroenterol Hepatol (2017) 0.75
Silencing speckle-type POZ protein by promoter hypermethylation decreases cell apoptosis through upregulating Hedgehog signaling pathway in colorectal cancer. Cell Death Dis (2016) 0.75
Bowel cancer categorisation into four subtypes could help to guide treatment, doctors say. BMJ (2015) 0.75
CIMT 2016: Mechanisms of efficacy in cancer immunotherapy - Report on the 14th Annual Meeting of the Association for Cancer Immunotherapy May 10-12 2016, Mainz, Germany. Hum Vaccin Immunother (2016) 0.75
Pan-organ transcriptome variation across 21 cancer types. Oncotarget (2016) 0.75
Colorectal and gastric cancer in 2015: The development of new agents and molecular classifications. Nat Rev Clin Oncol (2015) 0.75
Circulating cytokeratin-positive cells and tumor budding in colorectal cancer. World J Clin Oncol (2016) 0.75
Long-Term Culture of Intestinal Cell Progenitors: An Overview of Their Development, Application, and Associated Technologies. Curr Pathobiol Rep (2016) 0.75
HIC1 Expression Distinguishes Intestinal Carcinomas Sensitive to Chemotherapy. Transl Oncol (2016) 0.75
Therapy: Colorectal cancer: how to teach an old drug new tricks. Nat Rev Gastroenterol Hepatol (2016) 0.75
Favorable prognosis in colorectal cancer patients with co-expression of c-MYC and ß-catenin. BMC Cancer (2016) 0.75
Tumor Microenvironment in Gene Signatures: Critical Biology or Confounding Noise? Clin Cancer Res (2016) 0.75
Gene Signature in Sessile Serrated Polyps Identifies Colon Cancer Subtype. Cancer Prev Res (Phila) (2016) 0.75
Colon cancer subtypes: concordance, effect on survival and selection of the most representative preclinical models. Sci Rep (2016) 0.75
A multidimensional network approach reveals microRNAs as determinants of the mesenchymal colorectal cancer subtype. Oncogene (2016) 0.75
Identification of miRNA-mRNA Modules in Colorectal Cancer Using Rough Hypercuboid Based Supervised Clustering. Sci Rep (2017) 0.75
Biomarker in Colorectal Cancer. Cancer J (2016) 0.75
OncoScape: Exploring the cancer aberration landscape by genomic data fusion. Sci Rep (2016) 0.75
TRAP1 protein signature predicts outcome in human metastatic colorectal carcinoma. Oncotarget (2017) 0.75
Tumor-Initiating Cells: a criTICal review of isolation approaches and new challenges in targeting strategies. Mol Cancer (2017) 0.75
Genomic profiling of stage II and III colon cancers reveals APC mutations to be associated with survival in stage III colon cancer patients. Oncotarget (2016) 0.75
Predictive and Prognostic Molecular Biomarkers for Response to Neoadjuvant Chemoradiation in Rectal Cancer. Int J Mol Sci (2017) 0.75
Major milestones in translational oncology. BMC Med (2016) 0.75
Integrating tumor microenvironment with cancer molecular classifications. Genome Med (2015) 0.75
Impact of Microsatellite Instability in Signet-Ring Cell and Mucinous Components in Patients With Colorectal Carcinoma. Ann Coloproctol (2016) 0.75
A potential role for CCN2/CTGF in aggressive colorectal cancer. J Cell Commun Signal (2016) 0.75
Pan-cancer subtyping in a 2D-map shows substructures that are driven by specific combinations of molecular characteristics. Sci Rep (2016) 0.75
Antiangiogenic therapy for refractory colorectal cancer: current options and future strategies. Ther Adv Med Oncol (2016) 0.75
Stratified analysis reveals chemokine-like factor (CKLF) as a potential prognostic marker in the MSI-immune consensus molecular subtype CMS1 of colorectal cancer. Oncotarget (2016) 0.75
Germline miRNA DNA variants and the risk of colorectal cancer by subtype. Genes Chromosomes Cancer (2016) 0.75
MicroRNAs in the etiology of colorectal cancer: pathways and clinical implications. Dis Model Mech (2017) 0.75
Key Roles of AXL and MER Receptor Tyrosine Kinases in Resistance to Multiple Anticancer Therapies. Curr Oncol Rep (2017) 0.75
Promoter methylation of ITF2, but not APC, is associated with microsatellite instability in two populations of colorectal cancer patients. BMC Cancer (2016) 0.75
Prediction of overall survival in stage II and III colon cancer beyond TNM system: a retrospective, pooled biomarker study. Ann Oncol (2017) 0.75
The Influence of BRAF and KRAS Mutation Status on the Association between Aspirin Use and Survival after Colon Cancer Diagnosis. PLoS One (2017) 0.75
Heterogeneity of colorectal cancer risk by tumour characteristics: Large prospective study of UK women. Int J Cancer (2016) 0.75
Colorectal Choriocarcinoma in a Patient with Probable Lynch Syndrome. Front Oncol (2016) 0.75
Colon cancer modulation by a diabetic environment: A single institutional experience. PLoS One (2017) 0.75
Fatty acid-binding protein 1 is preferentially lost in microsatellite instable colorectal carcinomas and is immune modulated via the interferon γ pathway. Mod Pathol (2016) 0.75
The significance of tumor-associated immune response in molecular taxonomy, prognosis and therapy of colorectal cancer patients. Ann Transl Med (2016) 0.75
A new simple morphology-based risk score is prognostic in stage I/II colon cancers. Cancer Med (2016) 0.75
Bioconductor: open software development for computational biology and bioinformatics. Genome Biol (2004) 143.19
Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A (2001) 132.88
Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell (2005) 96.87
Comprehensive molecular characterization of human colon and rectal cancer. Nature (2012) 34.13
affy--analysis of Affymetrix GeneChip data at the probe level. Bioinformatics (2004) 32.08
Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci U S A (2002) 30.32
RAS is regulated by the let-7 microRNA family. Cell (2005) 30.24
An efficient algorithm for large-scale detection of protein families. Nucleic Acids Res (2002) 25.81
RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics (2011) 25.76
Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science (2006) 24.54
Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics (2006) 22.61
The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev (2008) 15.01
Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst (2004) 14.97
CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet (2006) 13.63
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med (2015) 13.08
Comprehensive molecular characterization of gastric adenocarcinoma. Nature (2014) 11.93
Absolute quantification of somatic DNA alterations in human cancer. Nat Biotechnol (2012) 10.87
Metagenes and molecular pattern discovery using matrix factorization. Proc Natl Acad Sci U S A (2004) 10.47
Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell (2012) 7.36
Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature (2013) 6.53
A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat Med (2013) 6.09
arrayQualityMetrics--a bioconductor package for quality assessment of microarray data. Bioinformatics (2008) 5.95
Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors. J Clin Oncol (2002) 5.91
Frozen robust multiarray analysis (fRMA). Biostatistics (2010) 5.57
Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. Cancer Res (2011) 5.30
The intestinal stem cell signature identifies colorectal cancer stem cells and predicts disease relapse. Cell Stem Cell (2011) 4.79
An integrated database of genes responsive to the Myc oncogenic transcription factor: identification of direct genomic targets. Genome Biol (2003) 4.49
The Intestinal Wnt/TCF Signature. Gastroenterology (2006) 4.48
Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions. Nat Med (2013) 4.22
A gene expression bar code for microarray data. Nat Methods (2007) 4.20
Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell (2014) 4.17
Comprehensive identification of mutational cancer driver genes across 12 tumor types. Sci Rep (2013) 3.92
Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol (2009) 3.69
Proteogenomic characterization of human colon and rectal cancer. Nature (2014) 3.61
The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov (2014) 3.32
Gene expression patterns of human colon tops and basal crypts and BMP antagonists as intestinal stem cell niche factors. Proc Natl Acad Sci U S A (2007) 3.20
Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive value. Clin Cancer Res (2012) 3.07
Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value. PLoS Med (2013) 2.96
Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun (2013) 2.94
p53 regulates epithelial-mesenchymal transition through microRNAs targeting ZEB1 and ZEB2. J Exp Med (2011) 2.93
Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer (2011) 2.68
Hypoxic and Ras-transformed cells support growth by scavenging unsaturated fatty acids from lysophospholipids. Proc Natl Acad Sci U S A (2013) 2.57
Identification of molecular subtypes of gastric cancer with different responses to PI3-kinase inhibitors and 5-fluorouracil. Gastroenterology (2013) 2.46
CD4⁺ follicular helper T cell infiltration predicts breast cancer survival. J Clin Invest (2013) 2.18
EMT is the dominant program in human colon cancer. BMC Med Genomics (2011) 2.05
Biomolecular network reconstruction identifies T-cell homing factors associated with survival in colorectal cancer. Gastroenterology (2009) 2.01
Random forests for genomic data analysis. Genomics (2012) 1.98
Developing predictive molecular maps of human disease through community-based modeling. Nat Genet (2012) 1.88
Gene expression patterns unveil a new level of molecular heterogeneity in colorectal cancer. J Pathol (2013) 1.71
Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transition. Int J Cancer (2013) 1.60
Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes. Gastroenterology (2014) 1.57
Default Prior Distributions and Efficient Posterior Computation in Bayesian Factor Analysis. J Comput Graph Stat (2009) 1.45
MiR-143 acts as a tumor suppressor by targeting N-RAS and enhances temozolomide-induced apoptosis in glioma. Oncotarget (2014) 1.44
Transcriptomic analysis comparing tumor-associated neutrophils with granulocytic myeloid-derived suppressor cells and normal neutrophils. PLoS One (2012) 1.40
Subtypes of primary colorectal tumors correlate with response to targeted treatment in colorectal cell lines. BMC Med Genomics (2012) 1.39
MYC through miR-17-92 suppresses specific target genes to maintain survival, autonomous proliferation, and a neoplastic state. Cancer Cell (2014) 1.36
Comparison of stable human Treg and Th clones by transcriptional profiling. Eur J Immunol (2009) 1.23
Colon cancer molecular subtypes identified by expression profiling and associated to stroma, mucinous type and different clinical behavior. BMC Cancer (2012) 1.23
A comprehensive DNA methylation profile of epithelial-to-mesenchymal transition. Cancer Res (2014) 1.06
Capturing the metabolomic diversity of KRAS mutants in non-small-cell lung cancer cells. Oncotarget (2014) 1.04
Molecular signatures mostly associated with NK cells are predictive of relapse free survival in breast cancer patients. J Transl Med (2013) 1.03
Context-dependent interpretation of the prognostic value of BRAF and KRAS mutations in colorectal cancer. BMC Cancer (2013) 1.02
Bayesian Gaussian Copula Factor Models for Mixed Data. J Am Stat Assoc (2013) 1.02
A robust genomic signature for the detection of colorectal cancer patients with microsatellite instability phenotype and high mutation frequency. J Pathol (2012) 1.00
β-Catenin promotes colitis and colon cancer through imprinting of proinflammatory properties in T cells. Sci Transl Med (2014) 0.96
Combining tumor genome simulation with crowdsourcing to benchmark somatic single-nucleotide-variant detection. Nat Methods (2015) 1.67
Global optimization of somatic variant identification in cancer genomes with a global community challenge. Nat Genet (2014) 1.21
Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathway. Nat Genet (2015) 1.15
CRISPR knockout screening outperforms shRNA and CRISPRi in identifying essential genes. Nat Biotechnol (2016) 1.04
First, design for data sharing. Nat Biotechnol (2016) 0.93
Bcl-2 is a critical mediator of intestinal transformation. Nat Commun (2016) 0.87
Opportunities and challenges provided by crosstalk between signalling pathways in cancer. Oncogene (2015) 0.84
CFTR is a tumor suppressor gene in murine and human intestinal cancer. Oncogene (2016) 0.83
Targeting the RB-E2F pathway in breast cancer. Oncogene (2016) 0.81
Reply to Colorectal cancer classification based on gene expression is not associated with FOLFIRI response. Nat Med (2014) 0.78
BRAF V600E Mutant Colorectal Cancer Subtypes Based on Gene Expression. Clin Cancer Res (2016) 0.76
Cancer stem cells don't waste their time cleaning-low proteasome activity, a marker for cancer stem cell function. Ann Transl Med (2016) 0.75
Polycomb complex PRC1 as gatekeeper of intestinal stem cell identity. Stem Cell Investig (2016) 0.75
A multidimensional network approach reveals microRNAs as determinants of the mesenchymal colorectal cancer subtype. Oncogene (2016) 0.75
Functional oncogene signatures guide rationally designed combination therapies to synergistically induce breast cancer cell death. Oncotarget (2016) 0.75
Quantitative, in situ analysis of mRNAs and proteins with subcellular resolution. Sci Rep (2017) 0.75
Androgen receptor inhibitor-induced "BRCAness" and PARP inhibition are synthetically lethal for castration-resistant prostate cancer. Sci Signal (2017) 0.75
Combating subclonal evolution of resistant cancer phenotypes. Nat Commun (2017) 0.75
Systematic discovery of mutation-specific synthetic lethals by mining pan-cancer human primary tumor data. Nat Commun (2017) 0.75